You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:

Continue

Go back

MLT_GIB/OTH/0007/17m
Date of preparation: March 2018

Top

Relvar Salford Lung Study (SLS) – pioneering asthma results

SLS asthma is the world’s first large prospective asthma effectiveness randomised controlled trial (RCT). With a patient population of 4,233, the trial measured the effectiveness and safety when initiating Relvar compared with continuing usual care (ICS or ICS/LABA), which was based on GPs decision. 12

What makes this trial pioneering, is that it reflected every day clinical practice and included a broad patient population. 12

A broad patient population, broad results

With broad inclusion criteria, the trial was designed to reflect the kind of patients that you see in your clinical practice:

1. Broad patient population: patients with co-morbidities, polypharmacy, smokers were allowed 13
2. Primary care setting: everyday clinical practice where most asthma patients are treated 124
3. Minimal intervention: patient monitoring and data collection via electronic records, which allowed minimal study intervention 12

A trial designed to reflect everyday clinical setting

The SLS asthma study compared the effectiveness of Relvar with usual care based on GP decision (ICS or ICS/LABA). 3,026 and 4,233 patients comprised the PEA and ITT respectively. 12

Broad population: >90% of patients screened were randomised for inclusion. 12 RCTs often have strict exclusion criteria meaning that <5% of the overall asthma population is studied. 5

Usual care as comparator: patients comprised the PEA and ITT respectively, 34% were on ICS and 66% on ICS/LABA (PEA). 2

  • Primary endpoint: Asthma Control Test™ (ACT) improvement of ≥3 or total ACT ≥20 in patients initiating Relvar vs. continuing usual care* at Month 6 in the Primary Effectiveness Analysis (PEA) population. 1

Improved control by initiating Relvar

Relvar improved asthma control* in significantly more patients, vs. continuing on ICS, in everyday clinical practice 1*†

Improvements sustained at 12 months

Consistent and sustained superiority vs ICS throughout the 12 month study 1

Patients in this subset were initiated with Relvar (324/440) or continued on ICS (259/454), in line with the Relvar EU licence. 16

This study represents a broad population of patients where 3,026 and 4,233 patients comprised the PEA and ITT respectively, 34% were on ICS and 66% on ICS/LABA (PEA). 1

The primary endpoint of the study was met (p<0.001). 1

Improvements offering meaningful benefits to patients 17-9

Relvar improved asthma control vs baseline which translates into meaningful benefits for your patients 1*†‡

Improvements that build on a wealth of Relvar data from other key studies

  • 24 hours of continuous efficacy with once-daily dosing 610
  • Superior reduction in rate of exacerbations vs ICS 11

...all in an easy-to-use inhaler 12

Discover more about Relvar >

Footnote

*Patients continued to receive treatment as prescribed by their GP. 2
Patients in this subset were initiated with Relvar (324/440) or continued on ICS (259/454).
Primary endpoint was Asthma Control Test™ (ACT) improvement of ≥3 or total ACT ≥20 in patients initiating Relvar vs. continuing usual care* at Month 6 in the Primary Effectiveness Analysis (PEA) population.
The PEA population consisted of all ITT patients with a total ACT <20 at baseline.
ACT is a trademark of Quality Metric Inc.
1

References

  1. Woodcock et al. Lancet 2017: http://dx.doi.org/10.1016/S0140-6736(17)32397-8 [Accessed: September 2017]
  2. Woodcock A et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015; 15:160.
  3. New JP et al. Obtaining real-world evidence: the Salford Lung Study. Thorax 2014; 69: 1152-4.
  4. Vermeire PA et al. Asthma control and differences in management practices across seven European countries. Resp Med 2002 Mar; 96(3): 142-9.
  5. Herland K et al. How representative are clinical study patients with asthma or COPD for a larger ‘‘real life’’ population of patients with obstructive lung disease? Respir Med 2005; 99: 11–19.
  6. Relvar Ellipta Summary of Product Characteristics, GlaxoSmithKline
  7. Schatz M et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009; 124: 719–723.
  8. Schatz M et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006; 117: 549–556.
  9. Nathan RA et al. Development of the Asthma Control Test: A survey for assessing asthma control. J Allergy Clin Immunol. 2004; 113: 59–65.
  10. Bernstein DI et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2015; 52(10): 1073–1083.
  11. Bateman ED et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014; 69: 312–319.
  12. Svedsater H et al. Ease of use of the ELLIPTA™ dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Resp Med. 2014; 24: 14019.

Relvar and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies